Diflumidone is a non-steroidal antiinflammatory drug. It inhibits the biosynthesis of prostaglandin by bovine seminal vesicle microsomes and arachidonic acid-induced aggregation of human platelets in a concentration-dependent manner. Diflumidone is a competitive inhibitor of prostaglandin synthetase. Diflumidone also inhibits equally the formation of PGE2 and PGF2a, which suggests blockade of endoperoxide formation. The relative topical efficacy of indomethacin and diflumidone for the suppression of ultraviolet-light-induced erythema has been compared in a randomized, double-blind, placebo-controlled study in man. At 24 h after application, the indomethacin-treated sites had significantly less erythema than did the diflumidone-treated sites.

Dilmefone is a pharmacological agent for increasing capillary wall strength. It was developed as a coronary vasodilator.

Dimabefylline an antiasthmatic, bronchospasmolytic drug. Also, it might be used as coronary dilator, cardiac stimulant.

Eptapirone is a potent, selective and efficacious 5-HT1A receptor agonist. In rats, it is readily bioavailable after oral administration. Likely, because of its high efficacy at 5-HT1A receptors, Eptapirone exerted powerful antidepressant- and anxiolytic-like activity in animal models. Eptapirone given in the evening suppresses REM (rapid eye movement) sleep more than buspirone and implies a greater central effect on serotonin receptors, which is consistent with the preclinical data that indicate it has greater efficacy than buspirone. It has little effect on other sleep stages. Eptapirone has been in phase I clinical trials for the treatment of anxiety and major depressive disorder. However, this research has been discontinued.

Ericolol is an antagonist of beta-adrenoreceptors. It exerts antihypertensive, antianginal and antiarrhythmic properties.

Eptastigmine or heptylphysostigmine is a competitive inhibitor of acetylcholinesterase. Eptastigmine leads to an improvement in the cerebral blood flow in the ischemic brain, excitatory and inhibitory effects on the gastrointestinal tract and to a protection from acute soman and diisopropylfluorophosphate intoxication. Eptastigmine, by either acute or chronic administration, has been found to have memory enhancing effects in different species of normal, aged and lesioned animals. It also restored to normal the age-related increase of EEG power without affecting spontaneous motor activity. Eptastigmine produces significant cognitive, clinical, and functional benefits in patients with probable Alzheimer's Disease. Although the cholinergic tolerability of eptastigmine was found to be favorable, its potential adverse hematologic effects limit its clinical utility.

Ersentilide (CK-3579 or HE93) is a blocker of beta1-adrenergic receptors and potassium channels. It exerts class III antiarrhythmic activity. It prevents ventricular fibrillation in a canine model of lethal arrhythmias.

Erbulozole (R 55104) is a water soluble congener of the microtubule inhibitor tubulozole, which has proven to possess anti-invasive, antitumoral and radiosensitizing capacities. Erbulozole development for the treatment of cancer has been discontinued.

Erizepine is a compound with neuroleptic activity. Erizepine is considered to bind dopamine receptors.